Mai-Jing Liao's Contact Details

Mai-Jing Liao's Company Details

RedCloud Bio

Shanghai, Shanghai, China • 2 Employees
Research

Founded in 2018, RedCloud Bio is an innovative biotech company integrating new technologies to advance small molecule drug discovery and development. The company has laboratories in Shanghai, Beijing and Xiamen, with its own small molecule drug research platform built upon structural pharmacology, molecular dynamics and AI technologies. With these capabilities, RedCloud Bio has accumulated structural data and algorithm models covering clinically important kinase targets, and has built an innovative pipeline targeting tumor resistance, rare disease and other critical diseases with high unmet medical needs. Its lead therapeutic candidate, H002, is a small molecule next generation TKI addressing EGFR activating mutations in NSCLC, expected to enter global clinical trials shortly.